Development of medications for alcohol use disorders: Recent advances and ongoing challenges

Expert Opinion on Emerging Drugs

Volumn 10, Issue 2, 2005, Pages 323-343

  Litten, Raye Z ^a   Fertig, Joanne ^a   Mattson, Margaret E ^a   Egli, Mark ^a  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

Alcohol dependence; Alcohol treatment; Alcohol use disorder; Medications; Pharmacological; Pharmacotherapy

Indexed keywords

1 AMINOCYCLOPROPANECARBOXYLIC ACID; 2 [1 (3 CHLORO 5 ISOPROPYLOXYCARBONYLAMINOPHENYL)ETHYLAMINO] 6 [2 (5 ETHYL 4 METHYL 1,3 THIAZOL 2 YL)ETHYL] 4 MORPHOLINOPYRIDINE; 3,7 DIMETHYL 1 PROPARGYLXANTHINE; 4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; 4 UREIDO 5,7 DICHLOROQUINOLINE; ACAMPROSATE; ADENOSINE A2 RECEPTOR ANTAGONIST; ALCOHOL DEHYDROGENASE; ANTICONVULSIVE AGENT; ARIPIPRAZOLE; BACLOFEN; BIOLOGICAL MARKER; CHOLINERGIC RECEPTOR STIMULATING AGENT; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; DISULFIRAM; DOPAMINE RECEPTOR STIMULATING AGENT; FLUOXETINE; FLUVOXAMINE; GABAERGIC RECEPTOR AFFECTING AGENT; GABAPENTIN; GENE PRODUCT; KUDZU EXTRACT; L 152804; MECAMYLAMINE; MEMANTINE; METHYLSCOPOLAMINE; NALMEFENE; NALPHA (DIPHENYLACETYL) N (4 HYDROXYBENZYL) DEXTRO ARGININAMIDE; NALTREXONE; NEUROPEPTIDE Y RECEPTOR AGONIST; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; NOCICEPTIN; ONDANSETRON; PLANT EXTRACT; PUERARIA LOBATA EXTRACT; PYRIDINE DERIVATIVE; QUINOLINE DERIVATIVE; RIMONABANT; RITANSERIN; SEROTONIN AGONIST; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROATE SEMISODIUM;

ADH1B GENE; ALCOHOL CONSUMPTION; ALCOHOLISM; ALDH2 GENE; ANIMAL BEHAVIOR; CHEMICAL COMPOSITION; CLINICAL TRIAL; COGNITION; COMORBIDITY; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SELF ADMINISTRATION; DRUG STRUCTURE; EATING DISORDER; FEEDING BEHAVIOR; FLUSHING; GABRA2 GENE; GABRA3 GENE; GENE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HEADACHE; HUMAN; HYPOTENSION; LIVER TOXICITY; MEMORY DISORDER; MOTIVATION; NAUSEA; NONHUMAN; PARESTHESIA; PATIENT COMPLIANCE; PHENOTYPE; POSTTRAUMATIC STRESS DISORDER; PSYCHOMOTOR PERFORMANCE; PUERARIA; PUERARIA LOBATA; QUALITY OF LIFE; RELAPSE; REVIEW; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; TACHYCARDIA; THORAX PAIN; TOBACCO DEPENDENCE; VOMITING; WEIGHT REDUCTION;

ALCOHOL-RELATED DISORDERS; CLINICAL TRIALS; DRUG INDUSTRY; DRUGS, INVESTIGATIONAL; HUMANS;

EID: 18844451509     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.10.2.323     Document Type: Review

References (214)

1. WORLD HEALTH ORGANIZATION (WHO): The World Health Report 2001 - Mental Health: New Understanding. New Hope World Health Organization, Geneva, Switzerland (2001).
2. GRANT BF, DAWSON DA, STINSON FS et al.: The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991 - 1992 and 2001-2002. Drug Alcohol Depend. (2004) 74:223-234.
3. SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMINISTRATION (SAMHSA), OFFICE OF APPLIED STUDIES: In: Results from the 2002 National Survey on Drug Use and Health: National Findings, Part 3, Alcohol. SAMHSA, Rockville, Maryland, USA (2003).
4. HARWOOD H: Updating estimates of the economic costs of alcohol abuse in the United States: Estimates, update methods and data. Report prepared by the Lewin group for the National Institute on Alcohol Abuse and Alcoholism. National Institute of Health Publications, Rockville, Maryland, USA (2000).
5. STINSON FS, NEPHEW TM, DUFOUR MC, GRANT BF: State trends in alcohol-related mortality, 1979-92. In: US Alcohol Epidemiologic Data Reference Manual. (Volume 5). National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland, USA (1996).
6. NIAAA: New advances in alcoholism treatment. Alcohol Alert (2000) 49:1-5.
7. FULLER RK, HILLER-STURMHOFEL S: Alcoholism treatment in the United States: an overview. Alcohol Res. Health (1999) 23:69-77.
8. MILLER WR, MEYERS RJ, HILLER-STURMHOFEL S: The community-reinforcement approach. Alcohol Res. Health (1999) 23:116-120.
9. FULLER RK, LITTEN RZ: Drugs to decrease alcohol consumption in humans: Aversive agents. In: The Pharmacology of Alcohol Abuse. Kranzler HR (Ed.), Springer-Verlag, Berlin, Germany (1995):369-381.
10. CHICK J: Safety issues concerning the use of disulfiram in treating alcohol dependence. Drug Safety (1999) 20:427-4435.
11. BANYS PL: The clinical use of disulfiram (Antabuse): a review. J. Psychoactive Drugs (1988) 20:243-260.
12. WRIGHT C, VAFIER JA, LAKE CR: Disulfiram-induced fulminating hepatitits: guidelines for liver-panel monitoring. J. Clin. Psychiatry. (1988) 49:430-434.
13. FULLER RK, BRANCHEY L, BRIGHTWELL DR et al.: Disulfiram treatment of alcoholism: a veterans administration cooperative study. JAMA (1986) 256:1449-1455.
14. ALLEN JP, LITTEN RZ: Techniques to enhance compliance with disulfiram. Alcohol Clin. Exp. Res. (1992) 16:1035-1041.
15. CHICK J, GOUGH K, FALKWOSKI W et al.: Disulfiram treatment of alcoholism. Br. J. Psychiatry (1992) 161:84-89.
16. CARROLL KM, NICH C, BALL SA, MCCANCE E, ROUNSAVILLE B: Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction (1998) 93:713-728.
17. CARROLL KM, FENTON LR, BALL SA et al.: Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial. Arch. Gen. Psychiatry (2004) 61:264-272.
18. FULLER RK, GORDIS E: Does disulfiram have a role in alcoholism treatment today? Addiction (2004) 99:21-24.
19. HART BW, FAIMAN MD: In vivo pharmacodynamic studies of the disulfiram metabolite 5-methyl N,N-diethylthiolcarbamate sulfoxide: inhibition of liver aldehyde dehydrogenase. Alcohol Clin. Exp. Res. (1994) 18:340-345.
20. VOLPICELLI JR, ALTERMAN AI, HAYASHIDA M, O'BRIEN CP: Naltrexone in the treatment of alcohol dependence. Arch. Gen. Psychiatry (1992) 49:876-880. This article was one of the first two published articles to show the efficacy of naltrexone.
21. O'MALLEY SS, JAFFE AJ, CHANG G, SCHOTTENFELD RS, MEYER RE, ROUNSAVILLE B: Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch. Gen. Psychiatry (1992) 49:881-887. This article was one of the first two published articles to show the efficacy of naltrexone.
22. ROHSENOW DJ: What place does naltrexone have in the treatment of alcoholism? CNS Drugs (2004) 18:547-560.
23. ANTON RF, SWIFT RM: Current pharmacotherapies of alcoholism: a US perspective. Am. J. Addict. (2003) 12:553-568.
24. CARMEN B, ANGELES M, ANA M, MARIA AJ: Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction (2004) 99:811-828. This review article conducted a meta-analysis of naltrexone and acamprosate.
25. KRANZLER HR, MODESTO-LOWE V, VAN KIRK J: Naltrexone versus nefazodone for treatment of alcohol dependence: a placebo-controlled trial. Neuropsychopharmacology (2000) 22:493-503.
26. KRYSTAL JH, CRAMER JA, KROL WF, KIRK GF, ROSENHECK RA: Naltrexone in the treatment of alcohol dependence. N. Engl. J. Med. (2001) 345:1734-1739.
27. GASTPAR M, BONNET U, BONING J et al.: Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study. J. Clin. Psychopharmacology (2002) 22:592-598.
28. DAVIDSON D, SAHA C, SCIFRES S, FYFFE J, O'CONNOR S, SELZER C: Naltrexone and brief counseling to reduce heavy drinking in hazardous drinkers. Addict. Behav. (2004) 29:1253-1258.
29. KRANZLER HR, VAN KIRK J: Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin. Exp. Res. (2001) 25:1335-1341. This review article conducted a meta-analysis of naltrexone and acramprosate.
30. STREETON C, WHELAN G: Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials. Alcohol Alcohol. (2001) 36:544-552. This review article conducted a meta-analysis of naltrexone.
31. CROOP RS, FAULKNER EB, LABRIOLA DF: The safety profile of naltrexone in the treatment of alcoholism: results from a multicenter usage study. Arch. Gen. Psychiatry (1997) 54:1130-1135.
32. DAVIDSON D, PALFAI T, BIRD C, SWIFT R: Effects of naltrexone on alcohol self-administration in heavy drinkers. Alcohol Clin. Exp. Res. (1999) 23:195-203.
33. MCCAUL ME, WAND GS, EISENBERG T, ROHDE CA, CHESKIN LJ: Naltrexone alters subjective and psychomotor responses to alcohol in heavy drinking subjects. Neuropsychopharmacology (2000) 22:480-492.
34. O'MALLEY SS, KRISHNAN-SARIN S, FARREN C, SINHA RAJITA, KREEK MJ: Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary- adrenocortical axis. Psychopharmacology (2002) 160:19-29.
35. DROBES DJ, ANTON RF, THOMAS SE, VORONIN K: Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers. Alcohol Clin. Exp. Res. (2004) 28:1362-1370.
36. KRANZLER HR, ARMELI S, FEINN R, TENNEN H: Targeted naltrexone treatment moderates the relations between mood and drinking behavior among problem drinkers. J. Consult. Clin. Psychol. (2004) 72:317-327.
37. ANTON RF, DROBES DJ, VORONIN K, DURAZO-AVIZU R, MOAK D: Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking. Psychopharmacology (2004) 173:32-40.
38. VOLPICELLI JR, RHINES KC, RHINES KC et al.: Naltrexone and alcohol dependence: Role of subject compliance. Arch. Gm. Psychiatry (1997) 54:737-742.
39. CHICK J, ANTON R, CHECINSKI K et al.: A muticentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol. (2000) 35:587-593.
40. MONTI PM, ROHSENOW DJ, SWIFT RM et al.: Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes. Alcohol Clin. Exp. Res. (2001) 25:1634-1647.
41. KRANZLER HR, WESSON DR, BILLOT L: Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial. Alcohol Clin. Exp. Res. (2004) 28:1051-1059.
42. GARBUTT JC, KRANZLER H, O'MALLEY SS et al.: Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA (2005) 293:1617-1625.
43. MCCAUL ME, WAND GS, EISSENBERG T, ROHDE CA, CHESKIN LJ: Naltrexone alters subjective and psychomotor responses to alcohol in heavy drinking subjects. Neuorpsycholpharmacology (2000) 22:480-492.
44. MCCAUL ME, WAND GS, ROHDE C, LEE SM: Serum 6-β-naltrexol levels are related to alcohol responses in heavy drinkers. Alcohol Clin. Exp. Res. (2000) 24:1385-1391.
45. HEINALA P, ALHO H, KIIANMAA K, LONNQVIST J, KKUOPPASALMI K, SINCLAIR JD: Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial. J. Clin. Psychopharmacol. (2001) 21:287-292.
46. KRANZLER HR, ARMELI S, TENNEN H et al.: Targeted naltrexone for early problem drinkers. J. Clin. Psychopharmacol. (2003) 23:294-304.
47. O'MALLEY SS, ROUNSAVILLE BJ, FARREN C et al.: Initial and maintenance naltrexone treatment for alcohol dependence using primary care versus specialty care. Arch. Intern. Med. (2003) 163:1695-1704.
48. OSLIN D, LIBERTO JG, O'BRIEN J, KROIS S, NORBECK J: Naltrexone as an adjunctive treatment for older patients with alcohol dependence. Am. J. Geriatr. Psychiatry (1997) 5:324-332.
49. PETRAKIS IL, O'MALLEY SS, ROUNSAVILLE B, POLING J, MCHUGH-STRONG C, KRYSTAL JH: Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychpharmacology (2004) 172:291-297.
50. MONTEROSSO JR, FLANNERY BA, PETTINATI HM et al.: Predicting treatment response to naltrexone: the influence of craving and family history. Am. J. Addict. (2001) 10:258-268.
51. OSLIN DW, BERRETTINI W, KRANZLER HR et al.: A functional polymorphism of the μ-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology (2003) 28:1546-1552.
52. MCCAUL ME, WAND GS, KIM YK, BENCHERIF B, DANNALS RF, FROST JJ: Naltrexone effects on μ- and δ-opioid receptor availability in alcohol dependence. Alcohol Clin. Exp. Res. (2003) 27:A21.
53. NAASSILA M, HAMMOUMI S, LEGRAND E, DURBIN P, DAOUST M: Mechanisms of action of acamprosate. Part I. Characterization of spermidine-sensitive acamprosate binding site in rat brain. Alcohol Clin. Exp. Res. (1998) 22:802-809.
54. POPP RL, LOVINGER D: Interaction of acamprosate with ethanol and spermine on NMDA receptors in primary cultured neurons. Eur. J. Pharmacol. (2000) 394:221-231.
55. HARRIS BR, PRENDERGAST MA, GIBSON DA et al.: Acamprosate inhibits the binding and neurotoxic effects of transA CPD, suggesting a novel site of action at metabotropic glutamate receptors. Alcohol Clin. Exp. Res. (2002) 26:1779-1793.
56. KOOB GF, MASON BJ, DEWITTE P, LITTLETON J, SIGGINS GR: Potential neuroprotective effects of acamprosate. Alcohol Clin. Exp. Res. (2002) 26:586-592.
57. MASON BJ, OWNBY RL: Acamprosate for the treatment of alcohol dependence: a review of double-blind, placebo-controlled trials. CNS Spectrums (2000) 5:58-69.
58. BRASSER SM, MCCAUL ME, HOUTSMULLER EJ: Alcohol effects during acamprosate treatment: a dose-response study in humans. Alcohol Clin. Exp. Res. (2004) 28:1074-1083.
59. MASON BJ, GOODMAN AM, DIXON RM et al.: A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone. Neuropsychopharmacohgy (2002) 27:596-606.
60. JOHNSON BA, O'MALLEY SS, CIRAULO DA et al.: Dose-ranging kinetics and behavioral pharmacology of naltrexone and acamprosate, both alone and combined, in alcohol-dependent subjects. J. Clin. Psychopharmacol. (2003) 23:281-293.
61. MANN K, LEHERT P, MORGAN MY: The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol Clin. Exp. Res. (2004) 28:51-63. This review article conducted a meta-analysis of acamprosate.
62. TEMPESTA E, JANIRI L, BIGNAMINI A, CHABAC S, POTGIETER A: Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study. Alcohol Alcohol. (2000) 35:202-209.
63. CHICK J, LEHERT P: Does acamprosate improve control of drinking as well as aiding abstinence? Drugs Ther. Perspect. (2003) 2:13-15.
64. VAN DEN BRINK W: The role of psychosocial interventions in the pharmacological treatment of alcohol dependence. Drugs Ther. Perspect. (2003) 2:16-21.
65. HAMMARBERG A, WENNBERG P, BECK O, FRANCK J: A comparison of two intensities of psychosocial intervention for alcohol dependent patients treated with acamprosate. Alcohol Alcohol. (2004) 39:251-255.
66. VERHEUL R, LEHERT P, GEERLINGS PJ, KOETER MW, VAN DEN BRINK W: Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients. Psychopharmacology (2005) 178(2-3):167-173.
67. MASON BJ, RITVO EC, MORGAN RO et al.: A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence. Alcohol Clin. Exp. Res. (1994) 18:1162-1167.
68. MASON BJ, SALVATO FR, WILLIAMS LD, RITVO EC, CUTLER R: A double-blind, placebo-controlled study or oral nalmefene for alcohol dependence. Arch. Gen. Psychiatry (1999) 56:719-724.
69. ANTON RF, PETTINATI H, ZWEBEN A et al.: A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence. J. Clin. Psychopharmacol. (2004) 24:421-428.
70. CONSTANTINI LC, KLEPPNER SR, MCDONOUGH J, AZAR MR, PATEL R: Implantable technology for long-term delivery of nalmefene for treatment of alcoholism. Int. J. Pharmaceutics (2004) 283:35-44.
71. 2-opioid receptor antagonist naltriben selectively attenuates alcohol intake in rats bred for alcohol preference. Pharmacol. Biochem. Behav. (1995) 52:153-159.
72. KRISHNAN-SARIN S, WAND GS, LI XW, LI T-K, PROTOGHESE PS, FROEHLICH JC: Effect of μ opioid receptor blockade on alcohol intake in rates bred for high alcohol drinking. Pharmacol. Biochem. Behav. (1998) 59:627-635.
73. PASTERNAK GW: Incomplete cross tolerance and multiple μ opioid peptide receptors. Trends Pharmacol. Sci. (2001) 22:67-70.
74. ASHTON H, YOUNG AH: GABA-ergic drugs: exit stage left, enter stage right. Psychopharmacology (2003) 17:174-178.
75. JOHNSON BA: Progress in the development of topiramate for treating alcohol dependence: from a hypothesis to a proof-of-concept study. Alcohol Clin. Exp. Res. (2004) 28:1137-1144.
76. JOHNSON BA, AIT-DAOUD N, BOWDEN CL et al.: Oral topiramate for treatment of alcohol dependence: a randomized controlled trial. Lancet (2003) 361:1677-1685. This was the first study to demonstrate an effect of topiramate in reducing drinking in alcohol-dependent patients.
77. JOHNSON BA, BA, AIT-DAOUD N, AKHTAR FZ, MA JZ: Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: a randomized controlled trial. Arch. Gen. Psychiatry (2004) 9:905-912.
78. JOHNSON BA: Topiramate-induced neuromodulation of cortico-mesolimbic dopamine function: a new vista for the treatment of comorbid alcohol and nicotine dependence? Addicted. Behav. (2004) 29:1465-1479.
79. KAMPMAN KM, PETTINATI H, LYNCH KG et al.: A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend. (2004) 75:233-240.
80. HARRIS JT, ROACHE JD, THORNTON JE: A role for valproate in the treatment of sedative-hypnotic withdrawal and for relapse prevention. Alcohol Alcohol. (2000) 35:319-323.
81. REOUX JP, SAXON AJ, MALTE CA, BAER JS, SLOAN KL: Diavlproex sodium in alcohol withdrawal: a randomized double-blind placebo-controlled clinical trial. Alcohol Clin. Exp. Res. (2001) 25:1324-1329.
82. LONGO LP, CAMPBELL TO, HUBATCH S: Divalproex sodium (Depakote) for alcohol and relapse prevention. J. Addict. Dis. (2002) 21:55-64.
83. BRADY KT, MYRICK H, HENDERSON S, COFFEY SF: The use of divalproes in alcohol relapse prevention: a pilot study. Drug Alcohol Depend. (2002) 67:323-330.
84. SALLOUM IM, CORNELIUS JR, DALEY DC, KIRISCI L, HIMMELHOCH JM, THASE ME: Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo controlled study. Arch. Gen. Psychiatry (2005) 62:37-45.
85. MARTINEZ-RAGA J, SABATER A, PEREZ-GALVES B, CASTELLANO M, CERVERA G: Add-on gabapentin in the treatment of opiate withdrawal. Prog. Neuro-Psychopharmacol. Biol. Psychiatry (2004) 28:599-601.
86. TAYLOR CP, GEE NS, SU T-Z et al.: A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res. (1998) 29:233-249.
87. MYRICK H, MALCOLM R, BRADY KT: Gabapentin treatment of alcohol withdrawal. Am. J. Psychiatry (1998) 155:1626.
88. BOZIKAS V, PETRIKIS P, GAMVRULA K, SAVVIDOU I, KARAVATOS A: Treatment of alcohol withdrawal with gabapentin. Prog. Neuro-Psychopharmacol. Biol. Psychiatry (2002) 26:197-199.
89. LITTEN RZ, ALLEN J, FERTIG J: Pharmacotherapies for alcohol problems: a review of research with focus on developments since 1991. Alcohol Clin. Exp. Res. (1996) 20:859-876.
90. ROBERTS AJ, MCARTHUR RA, HULL EE, POST C, KOOB GF: Effects of amperozide, 8-OH-DPAT, and FG 5974 on operant responding for ethanol. Psychopharmacology (1998) 137:25-32.
91. JOHNSON BA: Serotonergic agents and alcoholism treatment: rebirth of the subtype concept - a hypothesis. Alcohol Clin. Exp. Res. (2000) 24:1597-1601.
92. WILDE MI, MARKHAM A: Ondansetron: a review of its pharmacology and preliminary clinical findings in novel applications. Drug Eval. (1996) 52:773-794.
93. 3 receptor blockade: a preliminary study in healthy male volunteers. Psychopharmacology (1993) 112:142-144.
94. SWIFT RM, DAVIDSON D, WHELIHAN W, KUZNETSOV O: Ondansetron alters human alcohol intoxication. Biol. Psychiatry (1996) 40:514-521.
95. JOHNSON BA, ROACHE JD, JAVORS MA et al.: Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial. JAMA (2000) 284:963-971. This study demonstrated the effectiveness of ondansetron in reducing the frequency and amount of drinking in early-onset alcoholics.
96. JOHNSON BA, ROACHE JD, AIT-DAOUD N, ZANCA NA, VELAZQUES M: Ondansetron reduces the craving of biologically predisposed alcoholics. Psychopharmacology (2002) 160:408-413.
97. KRANZLER HR, PIERUCCI-LAGHA A, FEINN R, HERNANDEZ-AVILA C: Effects of ondansetron in early- versus late-onset alcoholics: a prospective, open-label study. Alcohol Clin. Exp. Res. (2003) 27:1150-1155.
98. FEINN R, NELLISSERY M, KRANZLER HR: Meta-analysis of the association of a functional serotonin transporter promoter polymorphism with alcohol dependence. Am. J. Med. Genet. (2005) 133:79-84.
99. GORELICK DA: Serotonin uptake blockers and the treatment of alcoholism. In: Recent Developments in Alcoholism (Volume 7) Treatment Research. Galanter M (Ed.), Plenum Press, New York, USA (1989):267-281.
100. KRANZLER HR: Pharmacotherapy of alcoholism: gaps in knowledge and opportunities for research. Alcohol Alcohol. (2000) 35:537-547.
101. PETTINATI HM, KRANZLER HR, MADARAS J: The status of serotonin-selective pharmacotherapy in the treatment of alcohol dependence. In: Recent Developments in Alcoholism (Volume 16) Research on Alcoholism Treatment. Galanter M (Ed.), Plenum Press, New York, USA (2003): 247-262.
102. KRANZLER HR, BURLESON JA, KORNER P et al.: Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. Am. J. Psychiatry (1995) 152:391-397.
103. KRANZLER HR, BURLESON JA, BROWN J, BABOR TF: Fluoxetine treatment seems to reduce the beneficial effects of cognitive-behavioral therapy in type B alcoholics. Alcohol Clin. Exp. Res. (1996) 20:1534-1541.
104. BABOR TF, HOFMANN M, DELBOCA FK et al.: Types of alcoholics, I: evidence for an empirically derived typology based on indicatiors of vulnerability and severity. Arch. Gen. Psychiatry (1992) 49:599-608.
105. PETTINATI HM, VOLPICELLI JR, KRANZLER HR, LUCK G, RUKSTALIS MR, CNAAN A: Sertraline treatment for alcohol dependence: interactive effects of medication and alcohol subtype. Alcohol Clin. Exp. Res. (2000) 24:1041-1049.
106. CHICK J, ASCHAUER H, HORNIK K et al.: Efficacy of fluvoxamine in preventing relapse in alcohol dependence: a one-year, double-blind, placebo-controlled multicentre study with analysis by typology. Drug Alcohol Depend. (2004) 74:61-70.
107. PETTINATI HM: Antidepressant treatment of co-occurring depression and alcohol dependence. Biol. Psychiatry (2004) 56:785-792. This article reviews the use of antidepressants to treat patients with comorbid alcohol and depression.
108. NUNES EV, LEVIN FR: Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis. JAMA (2004) 291:1887-1896. This review article conducted a meta-analysis of efficacy of antidepressant medications for treatment of combined depression and substance/alcohol use disorders.
109. A receptors containing α5 subunits in the CA1 and CA3 hippocampal fields regulate ethanol-motivated behaviors: an extended ethanol reward circuitry. J. Neurosci. (2001) 21:2166-2177.
110. 1 subtype in the ventral pallidum regulates alcohol-seeking behaviors. J. Neurosci. (2002) 22:3765-3775.
111. MORROW AL, VAN DOREN MJ, PENLAND SN, MATTHEWS DB: The role of GABAergic neuroactive steroids in ethanol action, tolerance and dependence. Brain Res. Rev. (2001) 37:98-109.
112. COUSINS MS, ROBERTS DCS, DE WIT H: GABAB receptor agonists for the treatment of drug addiction: a review of recent findings. Drug Alcohol Depend. (2002) 65:209-220.
113. ANSTROM KK, CROMWELL HC, MARKOWSKI T, WOODWARD DJ: Effect of baclofen on alcohol and sucrose self-administration in rats. Alcohol Clin. Exp. Res. (2003) 27:900-908.
114. COLOMBO G, VACCA G, SERRA S, BRUNETTI G, CARAI MAM, GESSA GL: Baclofen suppresses motivation to consume alcohol in rats. Psychopharmacology (2003) 167:221-224.
115. ADDOLORATO G, CAPUTO F, CAPRISTO E et al.: Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol. (2002) 37:504-508.
116. FLANNERY BA, GARBUTT JC, CODY MW et al: Baclofen for alcohol dependence: a preliminary open-label study. Alcohol Clin. Exp. Res. (2004) 28:1517-1523.
117. MCDONOUGH M, KENNEDY N, GLASPER A, BEARN J: Clinical features and management of gamma-hydroxyburyrate (GHB) withdrawal: a review. Drug Alcohol Depend. (2004) 75:3-9.
118. POLDRUGO F, ADDOLORATO G: The role of γ-hydroxybutyric acid in the treatment of alcoholism: from animal to clinical studies. Alcohol Alcohol. (1999) 34:15-24.
119. KOSTEN TR, GEORGE TP, KOSTEN TA: The potential of dopamine agonists in drug addiction. Expert Opin. Investig. Drugs (2002) 11:491-499.
120. NARANJO CA, DONGIER M, BREMNER KE: Long-acting injectable bromocriptine does not reduce relapse in alcoholics. Addiction (1997) 92:969-978.
121. MARRA D, WAROT D, BERLIN I, HISPARD E et al.: Amisulpride does not prevent relapse in primary alcohol dependence: results of a pilot randomized, placebo-controlled trial. Alcohol Clin. Exp. Res. (2002) 26:1545-1552.
122. WIESBECK GA, WEIJERS H-G, LESCH OM, GLASER T, TOENNES P-J, BOENING J: Flupenthixol decanoate and relapse prevention in alcoholics: results from a placebo-controlled study. Alcohol Alcohol. (2001) 36:329-334.
123. BONO G, BALDUCCI C, RICHELMI P, KOOB GF, PULVIRENTI L: Dopamine partial receptor agonists reduce ethanol intake in the rat. Eur. J. Pharmacol. (1996) 296:233-238.
124. Glutamate and Addiction. Herman BH, Frankenheim J, Litten RZ et al. (Eds), Humana Press, NJ, USA (2003). This book reviews the latest research on glutamate and drug and alcohol addiction.
125. HOLTER SM, DANYSZ W, SPANAGEL R: Evidence for alcohol anti-craving properties of memantine. Eur. J. Pharmacol. (1996) 314:R1-R2.
126. PIASECKI J, KOROS E, DYR W, KOSTOWSKI W, DANYSZ W, BIENKOWSKI P: Ethanol-reinforced behaviour in the rat: effects of uncompetitive NMDA receptor antagonist, memantine. Eur. J. Pharmacol. (1998) 354:135-143.
127. BISAGA A, EVANS SM: Acute effects of memantine in combination with alcohol in moderate drinkers. Psychopharmacology (2004) 172:16-24.
128. BACKSTROM P, BACHTELER D, KOCH S, HYYTIA P, SPANAGEL R: mGluR5 antagonist MPEP reduces ethanol-seeking and relapse behavior. Neuropsychopharmacology (2004) 29:921-928.
129. ξ-dependent mechanism. Mol. Pharmacol. (2005) 67(2):349-355.
130. BAPTISTA MAS, MARTIN-FARDON R, WEISS F: Preferential effects of the metabotropic glutamate 2/3 receptor agonist LY379268 on conditioned reinstatement versus primary reinforcement: comparison between cocaine and a potent conventional reinforcer. J. Neurosci. (2004) 24:4723-4727.
131. STROMBERG MF, VOLPICELLI JR, O'BRIEN CP, MACKLER SA: The NMDA receptor partial agonist, 1-aminocyclopropanecarboxylic acid (ACPC), reduces ethanol consumption in the rat. Pharmacol. Biochem. Behav. (1999) 64:585-590.
132. SNELL LD, CLAFFEY DJ, RUTH JA et al.: Novel structure having antagonist actions at both the glycine site of the N-methyl-D-aspartate receptor and neuronal voltage-sensitive sodium channels: biochemical, electrophysiological, and behavioral characterization. J. Pharmacol. Exp. Ther. (2000) 292:215-227.
133. NICOLL RA, ALGER BE: The brain's own marijuana. Sci. Am. (2004) 291:70-75.
134. DE FONSECA FR, DEL ARCO I, BERMUDEZ-SILVA FJ, BILBAO A, CIPPITELLI A, NAVARRO M: The endocannabinoid system: physiology and pharmacology. Alcohol Alcohol. (2005) 40:2-14.
135. HUNGUND BL, BASAVARAJAPPA BS, VADASZ C et al.: Ethanol, endocannabinoids, and the cannabinoidergic signaling system. Alcohol Clin. Exp. Res. (2002) 26:565-574.
136. BASAVARAJAPPA BS, HUNGUND BL: Neuromodulatory role of the endocannabinoid signaling system in alcoholism: an overview. Prostaglandins Leukot. Essent. Fatty Acids (2002) 66:287-299.
137. BASAVARAJAPPA BS, HUNGUND BL: Role of the endocannabinoid system in the development of tolerance to alcohol. Alcohol Alcohol. (2005) 40:15-24.
138. SERRA S, CARAI MAM, BRUNETTI G et al.: The cannabinoid receptor antagonist SR 141716 prevents acquisition of drinking behavior in alcohol-preferring rats. Eur. J. Pharmacol. (2001) 430:369-371.
139. 1 receptor antagonist, SR 141716, on alcohol's motivational properties in alcohol preferring rats. Eur. J. Pharmacol. (2004) 498:119-123.
140. FREEDLAND CS, SHARPE AL, SAMSON HH, PORRINO LJ: Effects of SR 141716A on ethanol and sucrose self-administration. Alcohol Clin. Exp. Res. (2001) 25:277-282.
141. BLACK SC: Cannabinoid receptor antagonists and obesity. Curr. Opin. Invest. Drugs (2004) 5:389-394.
142. NAVARRO M, CARRERA MR, DEL ARCO I, TRIGO JM, KOOB GF, DE FONSECA FR: Cannabinoid receptor antagonist reduces heroin self-administration only in dependent rats. Eur. J. Pharmacol. (2004) 501:235-237.
143. RYABININ AE, BACHTELL RK, HEINRICHS SC et al.: The corticotropin- releasing factor/urocortin system and alcohol. Alcohol Clin. Exp. Res. (2002) 26:714-722.
144. VALDEZ GR, ZORRILLA EP, ROBERTS AJ, KOOB GF: Antagonism of corticotrophin-releasing factor attenuates the enhanced responsiveness to stress observed during protracted ethanol abstinence. Alcohol (2003) 29:55-60.
145. LE AD, HARDING S, JUZYTSCH W, WATCHUS J, SHALEV U, SHAHAM Y: The role of corticotrophin-releasing factor in stress-induced relapse to alcohol-seeking behavior in rats. Psychopharmacology (2000) 150:317-324.
146. 1 receptor antagonist Antalarmin reduces volitional ethanol consumption in isolation-reared Fawn-Hooded rats. Neuroscience (2003) 117:243-247.
147. ZOBEL AW, NICKEL T, KUNZEL HE et al.: Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J. Psychiatric Res. (2000) 34:171-181.
148. 1 antagonist block the acquisition of opiate withdrawal-induced conditioned place aversion in rats. Neuropsychopharmacology (2005) 30:90-98.
149. 1 antagonists for anxiety. Expert Opin. Investig. Drugs (2004) 13:799-828.
150. BALE TL, CONTARINO A, SMITH GW et al.: Mice deficient for coticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nat. Genetics (2000) 24:410-414.
151. VALDEZ GR, SABINO V, KOOB GF: Increased anxiety-like behavior and ethanol self-administration in dependent rats: reversal via corticotrophin-releasing factor-2 receptor activation. Alcohol Clin. Exp. Res. (2004) 28:865-872.
152. THIELE TE, BADIA-ELDER NE: A role for neuropeptide Y in alcohol intake control: evidence from human and animal research. Physiol. Behav. (2003) 79:95-101.
153. SPARTA DR, FEE JR, HAYES DM, KNAPP DJ, NACNEIL DJ, THIELE TE: Perpheral and central administration of a selective neuropeptide Y Y1 receptor antagonist suppresses ethanol intake by C57BL/6J mice. Alcohol Clin. Exp. Res. (2004) 28:1324-1330.
154. KOOB GF: Alcoholism: allostasis and beyond. Alcohol Clin. Exp. Res. (2003) 27:232-243.
155. THIELE TE, KOH MT, PEDRAZZINI T: Voluntary alcohol consumption is controlled via the neuropeptide Y Y1 receptor. J Neurosci. (2002) 22:RC208.
156. SCHROEDER JP, OLIVE F, KOENIG H, HODGE CW: Intra-amygdala infusion of the NPY Y1 receptor antagonist BIBP 3226 attenuates operant ethanol self-administration. Alcohol Clin. Exp. Res. (2003) 27:1884-1891.
157. THORSELL A, RIMONDINI R, HEILIG M: Blockade of central neuropeptide Y (NPY) Y2 receptors reduces ethanol self-administration in rats. Neurosci. Lett. (2002) 332:1-4.
158. SCHROEDER JP, ILLER KA, HODGE CW: Neuropeptide-Y Y5 receptors modulate the onset and maintenance of operant ethanol self-administration. Alcohol Clin. Exp. Res. (2003) 27:1912-1920.
159. MAILLIARD WS, DIAMOND I: Recent advances in the neurobiology of alcoholism: the role of adenosine. Pharmacol. Ther. (2004) 101:39-46.
160. 2 receptors. Alcohol Clin. Exp. Res. (2004) 28:1308-1316.
161. KATNER SN, MCBRIDE WJ, LUMENG L, LI TK, MURPHY JM: Alcohol intake of P rats is regulated by muscarinic receptors in the pedunculopontine nucleus and VTA. Pharmacol. Biochem. Behav. (1997) 58:497-504.
162. SODERPALM B, ERICSON M, OLAUSSON P, BLOMQVIST O, ENGEL JA: Nicotinic mechanisms involved in the dopamine activating and reinforcing properties of ethanol. Behav. Brain Res. (2000) 113:85-96.
163. ERICSON M, BLOMQVIST O, ENGEL JA, SODERPALM B: Voluntary ethanol intake in the rat and the associated accumbal dopamine overflow are blocked by ventral tegmental mecamylamine. Eur. J. Pharmacol. (1998) 358:189-196.
164. BLOMQVIST O, HERNANDEZ-AVILA CA, VAN KIRK J, ROSE JE, KRANZLER HR: Mecamylamine modifies the pharmacokinetics and reinforcing effects of alcohol. Alcohol Clin. Exp. Res. (2002) 26:326-331.
165. CHI H, DE WIT H: Mecamylamine attenuates the subjective stimulant-like effects of alcohol in social drinkers. Alcohol Clin. Exp. Res. (2003) 27:780-786.
166. YOUNG EM, MAHLER S, CHI H, DE WIT H: Mecamylamine and ethanol preference in healthy volunteers. Alcohol Clin. Exp. Res. (2005) 29:58-65.
167. CICCOCIOPPO R, ECONOMIDOU D, FEDELI A et al.: Attenuation of ethanol self-administration and of conditioned reinstatement of alcohol-seeking behaviour by the antiopioid peptide nociceptin/orphanin FQ in alcohol-preferring rats. Psychopharmacology (2004) 172:170-178.
168. MARTIN-FARDON R, CICCOCIOPPO R, MASSI M, WEISS F: Nociceptin prevents stress-induced ethanol, but not cocaine-seeking behavior in rats. Neuropharmacology (2000) 11:1939-1943.
169. CICCOCIOPPO R, ECONOMIDOU D, FEDELI A, MASSI M: The nociceptin/orphanin FQ/NOP receptor system as a target for treatment of alcohol abuse: a review of recent work in alcohol-preferring rats. Physiol. Behav. (2003) 79:121-128.
170. KEUNG WM, VALLEE BL: Kudzu root: an ancient Chinese source of modern antidipsotropic agents. Phytochemistry (1998) 47:499-506.
171. KEUNG WM, VALLEE BL: Daidzin and daidzein suppress free-choice ethanol intake by Syrian Golden hamsters. Proc. Natl. Acad. Sci. (1993) 90:1008-10012.
172. OVERSTREET DH, LEE YW, REZVANI AH, PEI YH, CRISWELL HE, JANOWSKY DS: Suppression of alcohol intake after administration of the Chinese herbal medicine, NPI-028, and its derivatives. Alcohol Clin. Exp. Res. (1996) 20:221-227.
173. LIN RC, GUTHRIE S, XIE CY et al.: Isoflavonoid compounds extracted from Pueraria lobata suppress alcohol preference in a pharmacogenetic rat model of alcoholism. Alcohol Clin. Exp. Res. (1996) 20:659-663.
174. KEUNG WM, KLYOSOV AA, VALLEE BL: Daidzin inhibits mitochondrial aldehyde dehydrogenase and suppresses ethanol intake of Syrian golden hamsters. Proc. Natl. Acad. Sci. (1997) 94:1675-1679.
175. XIE CI, LIN RC, ANTONY V et al.: Daidzin, an antioxidant isoflavonoid, decreases blood alcohol levels and shortens sleep time induced by ethanol intoxication. Alcohol Clin. Exp. Res. (1994) 18:1443-1447.
176. 2C agonists. Pharmacol. Biochem. Behav. (2003) 75:619-625.
177. OLIVE MF, MEHMERT KK, MESSING RO, HODGE CW: Reduced operant ethanol self-administration and in vivo mesolimbic dopamine responses to ethanol in PKCε-deficienr mice. Eur. J. Neurosci. (2000) 12:4131-4140.
178. OLIVE MF, MEHMERT KK, NANNINI MA, CAMARINI R, MESSING RO, HODGE CW: Reduced ethanol withdrawal severity and altered withdrawal-induced c-fos expression in various brain regions of mice lacking protein kinase C-ε. Neuroscience (2001) 103:171-179.
179. BLEDNOW Y, WALKER D, HARRIS RA: Blockade of the leptin-sensitive pathway markedly reduces alcohol consumption in mice. Alcohol Clin. Exp. Res. (2004) 28:1683-1692.
180. LEWIS MJ, JOHNSON DF, WALDMAN D, LEIBOWITZ SF, HOEBEL BG: Galanin microinjection in the third ventricle increases voluntary ethanol intake. Alcohol Clin. Exp. Res. (2004) 28:1822-1828.
181. THIELE TE, STEWART RB, BADIA-ELDER NE et al.: Overlapping peptide control of alcohol self-adminisrration and feeding. Alcohol Clin. Exp. Res. (2004) 28:288-294.
182. CHOI D-S, CASCINI M-G, MAILLIARD W et al.: The Type 1 equilibrative nucleoside transporter regulates ethanol intoxication and preference. Nature Neurosci. (2004) 7:855-861.
183. 1 receptors modulate the anxiolytic-like effect of ethanol in the elevated plus-maze in mice. Eur. J. Pharmacol. (2004) 499:147-154.
184. 2-adrenoceptors in stress-induced reinstatement of alcohol seeking and alcohol self-administration in rats. Psychopharmacology (2005) 179:366-373.
185. LINTUNEN M, HYYTIA P, SALLMEN T et al.: Increased brain histamine in an alcohol-preferring rat line, and modulation of ethanol consumption by H3 receptor mechanisms. FASEB J. (2001) 15:1074-1076.
186. LIU X, WEISS F: Nitric oxide synthesis inhibition attenuates conditioned reinstatement of ethanol-seeking, but not the primary reinforcing effects of ethanol. Alcohol Clin. Exp. Res. (2004) 28:1194-1199.
187. SLAWECKI C, ROTH J: Neurokinin type-3 receptor stimulation impairs ethanol-associated appetitive behavior in Wistar rats. Alcohol Clin. Exp. Res. (2003) 27:1962-1970.
188. NIKOLAEV SV, BYCHKOV ER, LEBEDEV AA, DAMBINOVA SA: Mechanisms of the influences of the central administration of substance P on ethanol consumption in chronically alcoholic rat. Neurosci. Behav. Phsyiol. (2003) 33:905-909.
189. GARDELL LR, REID ML, CAVALLERO CA et al.: Amlodipine, a calcium channel inhibitor, and cocaine and ethanol's reinforcing effects. Pharmacol. Biochem. Behav. (1999) 64:567-572.
190. GATCH MB: Nitrendipine blicks the nociceptive effects of chronically administered ethanol. Alcohol Clin. Exp. Res. (2002) 26:1181-1187.
191. NEWTON PM, ORR CJ, WALLACE MJ, KIM C, SHIN H-S, MESSING RO: Deletion of N-type calcium channels alters ethanol reward and reduces ethanol consumption in mice. J. Neurosci. (2004) 24:9862-9869.
192. KIEFER F, JAHN H, TARNASKE T et al.: Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch. Gen. Psychiatry (2003) 60:92-99.
193. BESSON J, AEBY F, KASAS A, LEHERT P, POTGIETER A: Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alcohol Clin. Exp. Res. (1998) 22:573-579.
194. FARREN CK, REZVANI AH, OVERSTREET D, O'MALLEY S: Combination pharmacotherapy in alcoholism: a novel treatment approach. CNS Spectrums (2000) 5:70-76.
195. JOHNSON BA, AIT-DAOUD N, PRIHODA TJ: Combining ondansetron and naltrexone effectively treats biologically predisposed alcoholics: from hypotheses to preliminary clinical evidence. Alcohol Clin. Exp. Res. (2000) 24:737-742.
196. GALLATE JE, MALLET PE, MCGREGOR IS: Combined low dose treatment with opioid and cannabinoid receptor antagonists synergistically reduces the motivation to consume alcohol in rats. Psychopharmacology (2004) 173:210-216.
197. STROMBERG MF: The effect of baclofen alone and in combination with naltrexone on ethanol consumption in the rat. Pharmacol. Biochem. Behav. (2004) 78:743-750.
198. KOOB GF, AHMED SH, BOUTREL B et al.: Neurobiological mechanisms in the transition from drug use to drug dependence. Neurosci. Biobehav. Rev. (2004) 27:739-749.
199. ROBINSON TE, BERRIDGE KC: The psychology and neurobiology of addiction: an incentive-sensitization view. Addiction (2000) 95(Suppl. 2):S91-S117.
200. BYWATER RP: Location and nature of the residues important for ligand recognition in G-prorein coupled receptors. J. Mol. Recognit. (2005) 18(1):60-72.
201. MCGREGOR IS, GALLATE JE: Rats on the grog: novel pharmacotherapies for alcohol craving. Addict. Behav. (2004) 29:1341-1357.
202. LITTEN RZ, FERTIG J: Self-report and biochemical measures of alcohol consumption. Addiction (2003) 98(Suppl. 2):iii-iv.
203. ANTON RF, MOAK DH, WAID R, LATHAM PK, MALCOLM RJ, DIAS JK: Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am. J. Psychiatry (1999) 156:1758-1764.
204. DICK DM, FOROUD T: Candidate genes for alcohol dependence: a review of genetic evidence from human studies. Alcohol Clin. Exp. Res. (2003) 27:868-879.
205. CHEN CC, LU RB, CHEN YC, WANG MF et al.: Interaction between the functional polymorphisms of the alcohol-metabolism genes in protection against alcoholism. Am. J. Hum. Genet. (1999) 65:795-807.
206. DICK DM, EDENBERG JH, XUEI X et al.: Association of GABRG3 with alcohol dependence. Alcohol Clin. Exp. Res. (2004) 28:4-9.
207. A receptor, are associated with alcohol dependence and with brain oscillations. Am. J. Hum. Genet. (2004) 74:705-714.
208. ENOCH MA, XU K, FERRO E, HARRIS CR, GOLDMAN D: Genetic origins of anxiety in women: a role for a functional catechol-O-methyltransferase polymorphism. Psychiatr. Genet. (2003) 13:33-41.
209. OROSZI G, GOLDMAN D: Alcoholism: genes and mechanisms. Pharmacogenomics (2004) 5:1037-1048.
210. RAY LA, HUTCHISON KE: A polymorphism of the μ-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans. Alcohol Clin. Exp. Res. (2004) 28:1789-1795.
211. MARK TL, KRANZLER HR, POOLE VH, HAGEN CA, MCLEOD C, CROSSE S: Barriers to the use of medications to treat alcoholism. Am. J. Addict. (2003) 12:281-294.
212. THOMAS CP, WALLACK SS, LEE S, MCCARTY D, SWIFT R: Research to practice: adoption of naltrexone in alcoholism treatment. J. Subst. Abuse Treat. (2003) 24:1-11.
213. MCLELLAN AT, MEYERS K: Contemporary addiction treatment: a review of systems problems for adults and adolescents. Biol. Psychiatry (2004) 56:764-770. This article reviews the status of specialty treatment systems to identify and treat adolescents and adults suffering from alcohol and drug addiction.
214. WILLENBRING ML, KIVLAHAN D, KENNY M, GRILLO M, HAGEDORN H, POSTIER A: Beliefs about evidence-based practices in addiction treatment: a survey of Veterans Administration program leaders. J. Subst. Abuse Treat. (2004) 26:79-85.